Ampligen®, as the ‘chronic fatigue syndrome’ (ME/CFS) world knows, is an experimental immunomodulatory drug that’s been in trials for decades as a therapy for ME/CFS, and now faces delays in the FDA review process.
Developed by Hemispherx Biopharma, and most recently in tests as a treatment for H1N1 flu, Ampligen is “the only drug in any pipeline of any pharmaceutical company in the world which aims to become the standard treatment for CFS,” writes BioMedReports.com reporter ME Garza.
In the course of one day – May 28 - Garza observes, Ampligen was both the subject of a seeming “love-in” at the CFS Advisory Committee meeting in Washington, and the victim of a surprise attack in the investment press. “Just then, as countless CFS patients and Hemispherex Biopharma investors were watching" the live CFSAC video presentations, writes Garza, "something went ‘BOOM!’”
For the full action-packed story, and Garza's thinking about the factors impacting Ampligen's future, see “The Plot Thickens for Hemispherx Biopharma.” BioMedReports.com is a website for healthcare industry investors and traders.